Johnson & Johnson

Yahoo Finance • 18 days ago

Jim Cramer Says ‘Is It The Beginning Of The End Of Johnson & Johnson (JNJ)’s Multi-Year Legal overhang? Could Be’

We recently compiled a list of the Jim Cramer is Talking About These 14 Stocks Before Earnings.In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other stocks Jim Cramer is talking about b... Full story

Yahoo Finance • 19 days ago

More Patients On Eli Lilly's Mirikizumab Achieved Histologic Response At One Year Compared To Johnson & Johnson's Drug

More Patients On Eli Lilly's Mirikizumab Achieved Histologic Response At One Year Compared To Johnson & Johnson's Drug On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and effica... Full story

Yahoo Finance • 19 days ago

Is Johnson & Johnson (JNJ) Stock Set for Further Gains?

We recently published a list of 7 Most Profitable Cheap Stocks To Invest In. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other most profitable cheap stocks to invest in. Insights o... Full story

Yahoo Finance • 19 days ago

US stock futures drift with Q3 earnings, Fed speakers in spotlight

Investing.com--U.S. stock index futures drifted in muted trading Monday as investors hunkered down as the third-quarter earnings season picks up this week, while several Federal Reserve officials are scheduled to provide more cues on monet... Full story

Yahoo Finance • 23 days ago

J&J talc bankruptcy stays in Texas despite 'forum-shopping' opposition

By Dietrich Knauth NEW YORK (Reuters) - A Johnson & Johnson subsidiary can pursue its third attempt to resolve tens of thousands of lawsuits alleging its talc products caused cancer in a Texas bankruptcy court, a judge ruled on Thursday,... Full story

Yahoo Finance • 27 days ago

Is Johnson & Johnson (JNJ) the Best Stock to Buy According to Billionaire Ray Dalio?

We recently compiled a list of the Best Stocks to Buy According to Billionaire Ray Dalio. In this article, we will look at where Johnson & Johnson (NYSE:JNJ) ranks among the best stocks to buy according to billionaire Ray Dalio. Ray Dalio... Full story

Yahoo Finance • last month

55-Year-Old Who Reached $3,900 Per Month Income In Just 5 Years Shares Portfolio: Top 9 Stocks And ETFs

55-Year-Old Who Reached $3,900 Per Month Income In Just 5 Years Shares Portfolio: Top 9 Stocks And ETFs Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Research has shown that dividend... Full story

Yahoo Finance • last month

Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO®-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned

Results from CEPHEUS study highlight DARZALEX FASPRO® quadruplet regimen as a potential standard of care in newly diagnosed patients regardless of transplant eligibility New indication would be the first FDA-approved treatment regimen for... Full story

Yahoo Finance • last month

80 Hedge Funds Hold Stakes in Johnson & Johnson (JNJ) as of Q2 2024

We recently published a list of 8 Best Inexpensive Stocks To Invest In Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other best inexpensive stocks to invest in now. Are Experts... Full story

Yahoo Finance • last month

15 Best Dividend Stocks for Lifelong Passive Income

Dividend stocks offer a path to steady passive income, but not all are created equal. The key to long-term success lies in dividend sustainability, not just high current yields. The payout ratio serves as a critical tool for assessing sus... Full story

Yahoo Finance • last month

Johnson & Johnson announces updated results from Phase 1b RedirecTT-1 study

Johnson & Johnson announced updated results from the investigational Phase 1b RedirecTT-1 study evaluating the first-ever bispecific antibody combination of TALVEY, the first and only FDA-approved bispecific targeting GPRC5D, and TECVAYLI,... Full story

Yahoo Finance • last month

Johnson & Johnson provides updated results from Phase 1b TRIMM-2 study

Johnson & Johnson announced updated results from the investigational Phase 1b TRIMM-2 study evaluating the combination of TALVEY with DARZALEX FASPRO and pomalidomide in patients with relapsed or refractory multiple myeloma that demonstrat... Full story

Yahoo Finance • last month

DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma

Minimal residual disease (MRD)-negativity rate of 10-5 more than doubled by 12 months with DARZALEX FASPRO® in maintenance therapy compared to lenalidomide alone, resulting in improvement in 30-month progression-free survival RIO DE JANEI... Full story

Yahoo Finance • last month

Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment

Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment On Friday, Johnson & Johnson (NYSE:JNJ) released updated results from the investigational Phase 1b RedirecTT-1 study evaluating... Full story

Yahoo Finance • last month

Johnson & Johnson (JNJ): Leveraging Innovation for Sustained Market Leadership

We recently published a list of 7 Cheap Blue Chip Stocks to Invest in Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other cheap blue chip stocks. Should Investors Revisit the Idea o... Full story

Yahoo Finance • last month

Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients

Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients Thursday, the FDA approved Johnson & Johnson (NYSE:JNJ) Rybrevant (amivantamab-vmjw) in combination with sta... Full story

Yahoo Finance • last month

Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease

Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease Friday, the FDA approved  Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Miplyffa (arimoclomol), an oral medication for Neimann-Pick disease,... Full story

Yahoo Finance • last month

Johnson & Johnson (JNJ) Faces Legal Challenges While Advancing MedTech Innovations for Growth

We recently published a list of 10 Best Stocks For Beginners With Little Money. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other stocks for beginners with little money. “In my vie... Full story

Yahoo Finance • 2 months ago

Is Johnson & Johnson (JNJ) the Best Blue Chip Stock To Invest In According to Short Sellers?

We recently compiled a list of the 12 Best Blue Chip Stocks To Invest In According to Short Sellers. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other blue chip stocks. “Investors... Full story

Yahoo Finance • 2 months ago

RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer

Post-progression outcomes showed significant and sustained improvement for RYBREVANT® plus standard of care versus chemotherapy alone BARCELONA, Sept. 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced updated results f... Full story